Home > News > Arch raises $400 million venture fund
December 10th, 2007
Arch raises $400 million venture fund
Arch Venture Partners, the 21-year-old venture capital firm whose Seattle area investments include Allozyne, Trubion Pharmaceuticals and VLST, has raised a $400 million venture fund.
It is the firm's seventh fund. The money will be invested in early-stage companies in the biotechnology, advanced materials, nanotechnology and semiconductor sectors.
High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke December 4th, 2013
Nexttobe extends loan to Oasmia December 2nd, 2013
Harris & Harris Group Notes ABSMaterials' Series B Financing November 22nd, 2013
Harris & Harris Group Letter to Shareholders on Website November 18th, 2013
ASTM International Nanotechnology Committee Approves Airborne Nanoparticle Measurement Standard December 10th, 2013
Bruker Launches ContourSP 3D Optical Microscope for PCB Industry: Large-Format Metrology System Debuts to Over $5 Million in Orders December 10th, 2013
Nontoxic Quantum Dot Research Improves Solar Cells: Record power-conversion efficiency at Los Alamos from quantum-dot sensitized photovoltaics December 10th, 2013
New Method Presented for Production of Alpha SiAlON Single Phase Nanopowder December 10th, 2013